Business
TNI BioTech, Inc. Announces Distribution Agreement Between AHAR Pharma for Lodonal(TM) and TNI BioTech International, LTD for Nigerian Market
TNI BioTech, Inc. Announces Distribution Agreement Between AHAR Pharma for Lodonal(TM) and TNI BioTech International, LTD for Nigerian Market.
About this update from Biostax Corp.
[{"type":"text","content":"\n \n \n TNI BioTech, Inc. Announces Distribution Agreement Between AHAR Pharma for Lodonal(TM) and TNI BioTech International, LTD for Nigerian Market\n \n \nTNI BioTech, Inc. Announces Distribution Agreement Between AHAR Pharma for Lodonal(TM) and TNI BioTech International, LTD for Nigerian Market\n \n BETHESDA, MD--(Marketwired - Oct 2, 2013) - TNI BioTech, Inc. (OTCQB: TNIB), today announced TNI BioTech International, Ltd., its wholly owned British Virgin Islands subsidiary, signed a distribution agreement with AHAR Pharma, a Nigerian Company, to market Lodonal?, in Nigeria for the treatment of autoimmune diseases and cancer. \n Dr. Richard Afonja formed AHAR Pharma in 2013 for the sole purpose of marketing TNIB therapies. Dr. Afonja is a Hematologist/Oncologist and the Founder and CEO of a number of medical operations in both the United States and Nigeria for the treatment of cancer and blood disorders.\n AHAR intends to distribute Lodonal? through a local distributor network, an Internet client base and directly to hospitals, pharmacists and doctors in Nigeria.?Lodonal??(LDN) is an active immunotherapy with naltrexone provided in low doses as an oral medication. Lodonal? has been shown in clinical trials to rebalance the immune system in patients with autoimmune diseases, leading to decreased tissue inflammation, repair of damaged tissue and decreased symptoms.?\n Lodonal? can bind to opioid receptors on immune cells and also stimulate the production of both endogenous met-enkephalin and beta-endorphin, resulting in increased numbers of T cells and NK cells that destroy infectious organisms and cancer cells. \n TNI is in the process of submitting Phase 3 protocols for certain autoimmune diseases for FDA approval with respect to the drug.?\n Under the agreement AHAR will generate just over $53,000,000 in gross revenue for TNIB in 2014 with approximate $21,000,000 in available cash flow to meet TNI BioTech financial clinical trial commitments. AHAR has pre-paid for the API necessary for the soft launch and has committed to purchase a minimum of $1,000,000 of capsules between now and January 2014. \n \"AHAR is a dynamic and innovative Nigerian company. Their exceptional management has marketing experience in the region. Based on the combination of AHAR's regional marketing knowledge and financial commitment to the project I be...